Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2022
14,953
Period ended Jan 1, 2023
Change on a year earlier
-0.5%
15,035 in FY2021
History
8 years
Since FY2015
Sources
5
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Jan 1, 2023 | 14,953 | -0.5% | Form 10-K (filed 2023-02-16) ↗ |
| FY2021 | Jan 2, 2022 | 15,035 | +4.0% | Form 10-K (filed 2023-02-16) ↗ |
| FY2020 | Jan 3, 2021 | 14,450 | +4.0% | Form 10-K (filed 2023-02-16) ↗ |
| FY2019 | Dec 29, 2019 | 13,898 | +0.3% | Form 10-K (filed 2022-02-17) ↗ |
| FY2018 | Dec 30, 2018 | 13,853 | +1.8% | Form 10-K (filed 2021-02-22) ↗ |
| FY2017 | Dec 31, 2017 | 13,602 | +2.2% | Form 10-K (filed 2019-02-20) ↗ |
| FY2016 | Jan 1, 2017 | 13,307 | -1.5% | Form 10-K (filed 2019-02-20) ↗ |
| FY2015 | Jan 3, 2016 | 13,507 | – | Form 10-K (filed 2018-02-21) ↗ |
Breakdown
What makes up consumer health segment total [spun off as kenvue in fy2023q3] — worldwide sales ($m)
- Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — U.S. sales ($M)6,599 · FY2022
- Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — International sales ($M)8,354 · FY2022
- Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — Worldwide reported growth YoY (%)-0.5% · FY2022
- Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — Worldwide operational (constant-currency) growth YoY (%)3.6% · FY2022
- Consumer Health — Worldwide adjusted operational growth ex-A&D YoY (%)3.9% · FY2022
- Over-the-Counter (OTC) Medicines (TYLENOL, MOTRIN, ZYRTEC) — Worldwide sales ($M)6,031 · FY2022
- Skin Health / Beauty (NEUTROGENA, AVEENO) — Worldwide sales ($M)4,352 · FY2022
- Oral Care (LISTERINE) — Worldwide sales ($M)1,505 · FY2022
- Baby Care (JOHNSON'S) — Worldwide sales ($M)1,461 · FY2022
- Women's Health — Worldwide sales ($M)904 · FY2022
- Wound Care / Other (BAND-AID) — Worldwide sales ($M)700 · FY2022
Cite this data
StockData. (2026). Johnson & Johnson Consumer Health Segment Total [spun off as Kenvue in FY2023Q3] — Worldwide sales ($M) ($M), annual FY2015–FY2022 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_consumer_legacy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.